TL;DR
Somatic mutations in the estrogen receptor alpha (ERα), Y537S and D538G, are a major cause of acquired resistance to breast cancer endocrine therapies. This study reveals that these mutations stabilize ERα in an "on" state, allowing it to recruit coactivators even without estrogen, and also makes it resistant to anti-estrogen drugs by altering the conformation of a key structural element.
What Problem Does This Paper Address?
Breast cancer is a significant health challenge, and for many patients, hormone-based therapies targeting the estrogen receptor alpha (ERα) are highly effective. However, a substantial portion of these cancers eventually become resistant to these treatments, leading to recurrence. This acquired resistance is often linked to specific mutations in the ESR1 gene, which encodes ERα. The most common of these mutations, Y537S and D538G, are known to confer resistance, but the precise molecular mechanisms by which they achieve this have remained unclear. This paper aims to bridge that gap by providing a detailed biophysical and structural explanation for how these mutations lead to a constitutively active and antiestrogen-resistant ERα.
Methods
The researchers employed a multi-pronged approach to investigate the molecular basis of ERα mutations:
- Biophysical Assays:
- Time-resolved Förster Resonance Energy Transfer (tr-FRET): Used to measure the binding affinity of coactivator proteins (specifically SRC3 NRD) to ERα in the presence and absence of ligands (estrogen and anti-estrogens).
- Radioligand Binding Assays: Employed to determine the binding affinities of estrogen (E2) and an anti-estrogen (4-hydroxytamoxifen, TOT) to wild-type (WT) and mutant ERα.
- Proteolytic Susceptibility Assays (Trypsin Digestion): Assessed the conformational dynamics of the H11-12 loop and Helix 12 (H12) region of ERα by measuring how easily they are degraded by trypsin under different ligand conditions.
- Hydrogen/Deuterium Exchange Mass Spectrometry (HDX-MS): A powerful technique to probe the conformational mobility and stability of different regions of the protein by measuring the exchange of hydrogen atoms with deuterium in solution.
- Structural Biology:
- X-ray Crystallography: Determined the high-resolution three-dimensional structures of the D538G mutant ERα in its apo (unliganded), agonist-bound (E2), and antagonist-bound (4-hydroxytamoxifen) states.
- Computational Modeling:
- Atomistic Molecular Dynamics (MD) Simulations: Used to simulate the dynamic behavior of the ERα protein over time, providing insights into conformational changes and flexibility, particularly for the Y537S mutant which was difficult to crystallize with an antagonist.
Datasets
Not explicitly discussed as datasets in the traditional machine learning sense. The study relies on:
- Existing Protein Structures: Utilized PDB codes (e.g., 1GWR, 3ERT, 2QXM) for wild-type ERα structures as references and starting points for modeling.
- Experimental Data: The primary "datasets" are the results from the biophysical assays and the newly determined crystal structures.
Key Insights and Ideas
- Constitutive Activity is Key: The mutations don't just make the receptor less inhibited; they actively make it more active on its own. This is a fundamental shift from normal receptor behavior.
- H12 is the Master Switch: The H11-12 loop and H12 helix are critical for regulating ERα's activity. Mutations here are like jamming the switch in the "on" position.
- Stabilized "On" State: The mutations stabilize ERα in a conformation that mimics the estrogen-bound state, allowing it to recruit coactivators even without estrogen. This is the basis of its constitutive activity.
- Altered Antagonist Binding: While the mutations reduce binding affinity for anti-estrogens, they also change how the receptor behaves when the antagonist does bind, making it resistant to inhibition.
- Differential Mutant Behavior: Y537S and D538G, while both conferring resistance, do so through slightly different conformational dynamics, with Y537S showing a more pronounced stabilization of the agonist state.
Key Results
- Coactivator Recruitment Without Hormone: Both Y537S and D538G mutants recruit the SRC3 coactivator in the absence of estrogen, unlike wild-type ERα. Y537S shows a significantly higher affinity for SRC3 NRD in the apo state compared to D538G.
- Reduced Ligand Affinity: The mutant ERα proteins exhibit reduced binding affinities for both the estrogen agonist (E2) and the anti-estrogen antagonist (4-hydroxytamoxifen, TOT). Specifically, TOT binding affinity is impaired approximately 8- and 10-fold for Y537S and D538G, respectively, compared to WT.
- Stabilized H11-12 Loop and H12: Proteolytic susceptibility assays show that the H11-12 loop and H12 are significantly more stable (less susceptible to degradation) in the mutant receptors, especially in the apo state, indicating a more rigid, pre-ordered conformation.
- Structural Basis for Agonist State: X-ray crystallography of D538G-E2 reveals conformational changes in the H11-12 loop that displace Y537, leading to a less packed conformation and a more accessible AF-2 cleft, consistent with an agonist-like state.
- Structural Basis for Antagonist Resistance: Crystal structures and MD simulations of the D538G-TOT complex show altered conformations of the H11-12 loop and H12, suggesting that the antagonist binding is less effective at inducing the inhibitory conformation.
Limitations and Future Work
- LBD Focus: The structural studies were primarily conducted on the ligand-binding domain (LBD) of ERα. The authors acknowledge that further studies on the full-length, multi-domain ERα are necessary to fully understand the impact of these mutations.
- Other ERα Aspects: Future work should investigate the effects of these mutations on other ERα functions, such as binding to other hormones or SERMs/SERDs, homodimer formation, DNA binding, and coactivator specificity.
- Clinical Relevance of New Drugs: The findings suggest that new antiestrogens designed to increase the dynamics of H12 or target the H11-12 loop might be more effective against resistant cancers. The authors highlight the potential of newly developed mixed SERM/SERDs and orally bioavailable SERDs (like AZ9496, bazedoxifene, GDC910, and RAD1901) for treating these resistant cancers.
Summary updated